堕胎药物市场，按药物类别（米非司酮、米索前列醇、匹托新、欣母沛、卡前列素）、配销通路（医院药房、零售药房、在线药房）-全球预测（2024 - 2032 ）

受技术突破导致开发更安全、更有效的堕胎药物、对方便和非侵入性堕胎方法的需求不断增长以及社会文化规范不断变化的推动，2024-2032年全球堕胎药物市场规模将以8.2%的复合年增长率增长关于生殖健康。

该市场的主要成长动力之一是全球对安全且方便的堕胎选择的需求不断增长。例如，世界卫生组织表示，到2030年，妇女生殖健康永续发展目标旨在实现普遍获得全面的性健康和生殖保健服务，包括计划生育、教育以及将生殖健康无缝纳入国家策略。随着人们对生殖健康和权利的认识不断增强，人们寻求安全有效的方法来管理意外怀孕。堕胎药物提供了一种非侵入性且方便的外科手术替代方案，使妇女在生育选择上拥有更大的自主权。此外，社会文化规范的变化、医疗技术的进步以及医疗基础设施的扩大等因素也导致了对堕胎药物的需求不断增长。

堕胎药物市场根据药物类别、配销通路和地区进行分类。

到 2032 年，欣母沛细分市场将录得健康估值，因为欣母沛能够有效诱导子宫收缩，这使其成为医疗保健提供者的首选。这种机制，加上其安全性和高成功率，使欣母沛成为寻求非手术堕胎手术的女性的一线治疗选择，特别是在怀孕中期。

2024 年至 2032 年，线上药局领域的堕胎药物市场份额将大幅成长。线上平台提供的便利性、隐私性和可近性使其在寻求堕胎药物的消费者中很受欢迎。此外，线上药局的激增可能会推动堕胎药物的大量销售，从而促进市场成长。

受生殖权利意识增强、医疗基础设施改善和医疗支出增加的推动，亚太地区堕胎药物产业将在 2032 年呈现巨大成长。由于人口众多以及生殖健康方面不断变化的社会文化规范，中国、印度和韩国等国家可能会引领该地区的市场扩张。随着可支配收入的增加和医疗保健成为优先事项，个人更愿意投资自己的福祉。医疗保健支出模式的这种转变与对包括生殖健康服务在内的一系列医疗服务的需求增加直接相关，从而促进了产业扩张。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 意外怀孕的发生率上升
    • 日益关注妇女的生殖权利
    • 医疗科技的进步
    • 提高认识和教育
  • 产业陷阱与挑战
    • 社会和文化耻辱
    • 某些药物的高成本和副作用
    • 严格的监管环境
• 成长潜力分析
• 监管环境
• 技术景观
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司市占率分析
• 公司矩阵分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按药物类别，2018 - 2032 年

• 主要趋势
• 米非司酮
• 米索前列醇
• 催产素
• 欣马巴特
• 卡前列素
• 其他药物类别

第 6 章：市场估计与预测：按配销通路划分，2018 年 - 2032 年

• 主要趋势
• 医院药房
• 零售药局
• 网路药局

第 7 章：市场估计与预测：按地区划分，2018 年 - 2032 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 欧洲其他地区
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋
  • 中东和非洲其他地区

第 8 章：公司简介

• Cipla Limited
• Endo International plc
• Exelgyn
• Gedeon Richter plc
• Jubilant Life Sciences
• Lupin Limited
• Mylan N.V.
• Pfizer Inc.
• Sun Pharmaceutical Industries
• Torrent Pharmaceuticals Ltd.
• Zydus Lifesciences Limited

Global Abortion Drugs Market Size will grow at 8.2% CAGR during 2024-2032, driven by technological breakthroughs leading to the development of safer and more effective abortion drugs., rising demand for convenient and non-invasive abortion methods, and changing socio-cultural norms regarding reproductive health.

One of the primary growth drivers for the market is the increasing demand for safe and accessible abortion options globally. For instance, according to WHO, by 2030, the SDG for women's reproductive health aims to achieve universal access to comprehensive sexual and reproductive healthcare services, encompassing family planning, education, and the seamless integration of reproductive health into national strategies. As awareness about reproductive health and rights continues to grow, individuals seek out safe and effective methods for managing unplanned pregnancies. Abortion drugs offer a non-invasive and convenient alternative to surgical procedures, providing women with greater autonomy over their reproductive choices. Additionally, factors such as changing socio-cultural norms, advancements in medical technology, and expanding healthcare infrastructure contribute to the rising demand for abortion drugs.

The Abortion Drugs Market is classified based on drug class, distribution channel, and region.

The hemabate segment will record a healthy valuation by 2032, owing to the effectiveness of hemabate in inducing uterine contractions, which makes it a preferred choice for healthcare providers. This mechanism, coupled with its safety profile and high success rates, positions Hemabate as a frontline treatment option for women seeking non-surgical abortion procedures, particularly in the second trimester.

The abortion drugs market share from the online pharmacies segment will grow substantially over 2024-2032. The convenience, privacy, and accessibility offered by online platforms have made them popular among consumers seeking abortion medications. Besides, the proliferation of online pharmacies could drive significant sales of abortion drugs, contributing to market growth.

Asia Pacific Abortion Drugs Industry will exhibit tremendous growth through 2032, driven by increasing awareness about reproductive rights, improving healthcare infrastructure, and rising healthcare expenditure. Countries like China, India, and South Korea could lead the market expansion in the region due to large populations and changing socio-cultural norms regarding reproductive health. As disposable incomes increase and healthcare becomes a priority, individuals are more willing to invest in their well-being. This shift in healthcare spending patterns directly correlates with an increased demand for a range of medical services, including reproductive health services, thereby contributing to industry expansion.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Base estimates & calculations
• 1.3 Data collection
• 1.4 Forecast calculations
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising incidence of unplanned pregnancies
    • 3.2.1.2 Increasing focus on women's reproductive rights
    • 3.2.1.3 Advancements in medical technology
    • 3.2.1.4 Increasing awareness and education
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Social and cultural stigma
    • 3.2.2.2 High cost and side-effects associated with certain drugs
    • 3.2.2.3 Stringent regulatory environment
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
• 3.6 Porter's analysis
  • 3.6.1 Supplier power
  • 3.6.2 Buyer power
  • 3.6.3 Threat of new entrants
  • 3.6.4 Threat of substitutes
  • 3.6.5 Industry rivalry
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Mifepristone
• 5.3 Misoprostol
• 5.4 Pitocin
• 5.5 Hemabate
• 5.6 Carboprost
• 5.7 Other drug classes

Chapter 6 Market Estimates and Forecast, By Distribution Channel, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Hospital pharmacies
• 6.3 Retail pharmacies
• 6.4 Online pharmacies

Chapter 7 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 UK
  • 7.3.3 France
  • 7.3.4 Spain
  • 7.3.5 Italy
  • 7.3.6 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 Japan
  • 7.4.2 China
  • 7.4.3 India
  • 7.4.4 Australia
  • 7.4.5 South Korea
  • 7.4.6 Rest of Asia Pacific
• 7.5 Latin America
  • 7.5.1 Brazil
  • 7.5.2 Mexico
  • 7.5.3 Argentina
  • 7.5.4 Rest of Latin America
• 7.6 Middle East and Africa
  • 7.6.1 South Africa
  • 7.6.2 Saudi Arabia
  • 7.6.3 UAE
  • 7.6.4 Rest of Middle East and Africa

Chapter 8 Company Profiles

• 8.1 Cipla Limited
• 8.2 Endo International plc
• 8.3 Exelgyn
• 8.4 Gedeon Richter plc
• 8.5 Jubilant Life Sciences
• 8.6 Lupin Limited
• 8.7 Mylan N.V.
• 8.8 Pfizer Inc.
• 8.9 Sun Pharmaceutical Industries
• 8.10 Torrent Pharmaceuticals Ltd.
• 8.11 Zydus Lifesciences Limited